Thursday, 29 Apr 2021 07:28 PM MYT
The underperformance of the cancer drugs was partially offset by better-than-expected sales of the blood thinner Eliquis that Bristol Myers shares with Pfizer Inc. Bristol Myers still expects full-year earnings in the range of US$7.35 to US$7.55 a share, Elkins said.Eliquis sales were US$2.89 billion, beating analyst expectations by about US$300 million. Revlimid had sales of US$2.94 billion, around US$150 million lower than Wall Street projections.
“Overall, I think we’re in a good place,” Elkins said, adding that he expects Eliquis’ growth to continue and Opdivo to return to growth in the second half of the year due to approvals in new tumor types and its increasing use as an initial treatment for advanced lung cancer.